Healio roundup: Key takeaways in psoriasis from Maui Derm 2022

Healio rounded up psoriasis coverage and expert analysis presented and discussed at Maui Derm for Dermatologists in Wailea, Hawaii.

Guselkumab treatment for psoriatic arthritis

Guselkumab was more effective in psoriasis skin clearance compared with most psoriatic arthritis (PsA) treatments, according to a presentation.

The meta-analysis included an evaluation of 15 PsA treatments, and Healio spoke with one of the researchers, Philip J. Mease, MD, a clinical professor at the University of Washington School of Medicine and director of rheumatology research at the Swedish Medical Center in Seattle, about the impact of this data. Read more.

Comorbidities of psoriatic disease

The use of biologics, liver risk factors related to the use of methotrexate and cardiovascular disease were the latest research topics discussed regarding comorbidities associated with PsA.

Healio spoke with Joel M. Gelfand, MD, MSCE, FAAD, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine and co-chair of the National Psoriasis Foundation COVID-19 Task Force, about these comorbidities and the importance of screening psoriasis patients. Watch.

National Psoriasis Foundation Task Force and COVID-19 vaccines

Treatments for psoriatic disease do not impact the risk for getting COVID-19 or experiencing poor COVID-19 outcomes, Gelfand shared in a Healio video.

Gelfand added that studies also show that psoriasis treatments, such as biologics and methotrexate, “have good uptake for mRNA vaccines” and the patients make “plenty of antibodies that are protective.” Watch.